Stephen Spellman

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5875472/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	HLA Match Likelihoods for Hematopoietic Stem-Cell Grafts in the U.S. Registry. New England Journal of Medicine, 2014, 371, 339-348.	27.0	861
2	<i>HLA-C</i> –Dependent Prevention of Leukemia Relapse by Donor Activating <i>KIR2DS1</i> . New England Journal of Medicine, 2012, 367, 805-816.	27.0	398
3	Effect of T-cell-epitope matching at HLA-DPB1 in recipients of unrelated-donor haemopoietic-cell transplantation: a retrospective study. Lancet Oncology, The, 2012, 13, 366-374.	10.7	289
4	The detection of donor-directed, HLA-specific alloantibodies in recipients of unrelated hematopoietic cell transplantation is predictive of graft failure. Blood, 2010, 115, 2704-2708.	1.4	249
5	Impact of allele-level HLA matching on outcomes after myeloablative single unit umbilical cord blood transplantation for hematologic malignancy. Blood, 2014, 123, 133-140.	1.4	239
6	CD16xCD33 bispecific killer cell engager (BiKE) activates NK cells against primary MDS and MDSC CD33+ targets. Blood, 2014, 123, 3016-3026.	1.4	220
7	HLA-C Antigen Mismatch Is Associated with Worse Outcome in Unrelated Donor Peripheral Blood Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2011, 17, 885-892.	2.0	196
8	Effect of donor–recipient HLA matching at HLA A, B, C, and DRB1 on outcomes after umbilical-cord blood transplantation for leukaemia and myelodysplastic syndrome: a retrospective analysis. Lancet Oncology, The, 2011, 12, 1214-1221.	10.7	192
9	Classification of HLA-Matching for Retrospective Analysis of Unrelated Donor Transplantation: Revised Definitions to Predict Survival. Biology of Blood and Marrow Transplantation, 2008, 14, 748-758.	2.0	186
10	Unrelated Donor Cord Blood Transplantation for Children with Severe Sickle Cell Disease: Results of One Cohort from the Phase II Study from the Blood and Marrow Transplant Clinical Trials Network (BMT CTN). Biology of Blood and Marrow Transplantation, 2012, 18, 1265-1272.	2.0	181
11	The graft-versus-leukemia effect using matched unrelated donors is not superior to HLA-identical siblings for hematopoietic stem cell transplantation. Blood, 2009, 113, 3110-3118.	1.4	147
12	Donor Killer Cell Ig-like Receptor B Haplotypes, Recipient HLA-C1, and HLA-C Mismatch Enhance the Clinical Benefit of Unrelated Transplantation for Acute Myelogenous Leukemia. Journal of Immunology, 2014, 192, 4592-4600.	0.8	139
13	Race and Socioeconomic Status Influence Outcomes of Unrelated Donor Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation, 2009, 15, 1543-1554.	2.0	135
14	National Marrow Donor Program HLA Matching Guidelines for Unrelated Adult Donor Hematopoietic Cell Transplants. Biology of Blood and Marrow Transplantation, 2008, 14, 45-53.	2.0	132
15	Chronic GVHD risk score: a Center for International Blood and Marrow Transplant Research analysis. Blood, 2011, 117, 6714-6720.	1.4	128
16	Fast and accurate HLA typing from short-read next-generation sequence data with xHLA. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, 8059-8064.	7.1	118
17	Optimal Practices in Unrelated Donor Cord Blood Transplantation for Hematologic Malignancies. Biology of Blood and Marrow Transplantation, 2017, 23, 882-896.	2.0	117
18	<i>KIR3DL1</i> / <i>HLA-B</i> Subtypes Govern Acute Myelogenous Leukemia Relapse After Hematopoietic Cell Transplantation. Journal of Clinical Oncology, 2017, 35, 2268-2278.	1.6	109

#	Article	IF	CITATIONS
19	Donor activating KIR3DS1 is associated with decreased acute GVHD in unrelated allogeneic hematopoietic stem cell transplantation. Blood, 2010, 115, 3162-3165.	1.4	99
20	Advances in the Selection of HLA-Compatible Donors: Refinements in HLA Typing and Matching over the First 20 Years of the National Marrow Donor Program Registry. Biology of Blood and Marrow Transplantation, 2008, 14, 37-44.	2.0	91
21	National Marrow Donor Program–Sponsored Multicenter, Phase II Trial of HLA-Mismatched Unrelated Donor Bone Marrow Transplantation Using Post-Transplant Cyclophosphamide. Journal of Clinical Oncology, 2021, 39, 1971-1982.	1.6	90
22	Allele-Level Haplotype Frequencies and Pairwise Linkage Disequilibrium for 14 KIR Loci in 506 European-American Individuals. PLoS ONE, 2012, 7, e47491.	2.5	85
23	HLA Mismatch Is Associated with Worse Outcomes after Unrelated Donor Reduced-Intensity Conditioning Hematopoietic Cell Transplantation: An Analysis from the Center for International Blood and Marrow Transplant Research. Biology of Blood and Marrow Transplantation, 2015, 21, 1783-1789.	2.0	83
24	Effect of HLA-Matching Recipients to Donor Noninherited Maternal Antigens on Outcomes after Mismatched Umbilical Cord Blood Transplantation for Hematologic Malignancy. Biology of Blood and Marrow Transplantation, 2012, 18, 1890-1896.	2.0	82
25	Improved survival after acute graft- <i>versus</i> -host disease diagnosis in the modern era. Haematologica, 2017, 102, 958-966.	3.5	79
26	Allele-level HLA matching for umbilical cord blood transplantation for non-malignant diseases in children: a retrospective analysis. Lancet Haematology,the, 2017, 4, e325-e333.	4.6	72
27	Prior rituximab correlates with less acute graftâ€versusâ€host disease and better survival in Bâ€cell lymphoma patients who received allogeneic peripheral blood stem cell transplantation. British Journal of Haematology, 2009, 145, 816-824.	2.5	66
28	Significance of Ethnicity in the Risk of Acute Graft-versus-Host Disease and Leukemia Relapse after Unrelated Donor Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2013, 19, 1197-1203.	2.0	63
29	The prognostic value of serum C-reactive protein, ferritin, and albumin prior to allogeneic transplantation for acute myeloid leukemia and myelodysplastic syndromes. Haematologica, 2016, 101, 1426-1433.	3.5	53
30	Role of HLA-B exon 1 in graft-versus-host disease after unrelated haemopoietic cell transplantation: a retrospective cohort study. Lancet Haematology,the, 2020, 7, e50-e60.	4.6	53
31	Effects of Mismatching for Minor Histocompatibility Antigens on Clinical Outcomes in HLA-Matched, Unrelated Hematopoietic Stem Cell Transplants. Biology of Blood and Marrow Transplantation, 2009, 15, 856-863.	2.0	47
32	A combined DPA1â^¼DPB1 amino acid epitope is the primary unit of selection on the HLA-DP heterodimer. Immunogenetics, 2012, 64, 559-569.	2.4	47
33	Unrelated Donor Hematopoietic Cell Transplantation: Factors Associated with a Better HLA Match. Biology of Blood and Marrow Transplantation, 2008, 14, 1334-1340.	2.0	46
34	Replication and validation of genetic polymorphisms associated with survival after allogeneic blood or marrow transplant. Blood, 2017, 130, 1585-1596.	1.4	45
35	HLA mismatching within or outside of cross-reactive groups (CREGs) is associated with similar outcomes after unrelated hematopoietic stem cell transplantation. Blood, 2007, 109, 4064-4070.	1.4	43
36	<i>KIR B</i> donors improve the outcome for AML patients given reduced intensity conditioning and unrelated donor transplantation. Blood Advances, 2020, 4, 740-754.	5.2	42

#	Article	IF	CITATIONS
37	HLAMatchmaker-Defined Triplet Matching Is Not Associated with Better Survival Rates of Patients with Class I HLA Allele Mismatched Hematopoietic Cell Transplants from Unrelated Donors. Biology of Blood and Marrow Transplantation, 2008, 14, 1064-1071.	2.0	40
38	Insufficient evidence for association of NOD2/CARD15 or other inflammatory bowel disease–associated markers on GVHD incidence or other adverse outcomes in T-replete, unrelated donor transplantation. Blood, 2010, 115, 3625-3631.	1.4	40
39	Tools for the Precision Medicine Era: How to Develop Highly Personalized Treatment Recommendations From Cohort and Registry Data Using Q-Learning. American Journal of Epidemiology, 2017, 186, 160-172.	3.4	40
40	Sibling versus Unrelated Donor Allogeneic Hematopoietic Cell Transplantation for Chronic Myelogenous Leukemia: Refined HLA Matching Reveals More Graft-versus-Host Disease but not Less Relapse. Biology of Blood and Marrow Transplantation, 2009, 15, 1475-1478.	2.0	39
41	A High Degree of HLA Disparity Arises From Limited Allelic Diversity: Analysis of 1775 Unrelated Bone Marrow Transplant Donor-Recipient Pairs. Human Immunology, 2007, 68, 30-40.	2.4	37
42	Impact of KIR and HLA Genotypes on Outcomes after Reduced-Intensity Conditioning Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation, 2015, 21, 1589-1596.	2.0	37
43	Establishment of Definitions and Review Process for Consistent Adjudication of Cause-specific Mortality after Allogeneic Unrelated-donor Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation, 2015, 21, 1679-1686.	2.0	37
44	Scoring HLA Class I Mismatches by HistoCheck Does Not Predict Clinical Outcome in Unrelated Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2012, 18, 739-746.	2.0	34
45	Influence of Age on Acute and Chronic GVHD in Children Undergoing HLA-Identical Sibling Bone Marrow Transplantation for Acute Leukemia: Implications for Prophylaxis. Biology of Blood and Marrow Transplantation, 2018, 24, 521-528.	2.0	34
46	Donor and recipient chemokine receptor CCR5 genotype is associated with survival after bone marrow transplantation. Blood, 2010, 115, 2311-2318.	1.4	32
47	Hematopoietic Cell Transplantation with Cord Blood for Cure of HIV Infections. Biology of Blood and Marrow Transplantation, 2013, 19, 393-397.	2.0	32
48	Guidelines for the development and validation of new potency assays for the evaluation of umbilical cord blood. Cytotherapy, 2011, 13, 848-855.	0.7	31
49	The Effect of the Composition of Unrelated Donor Bone Marrow and Peripheral Blood Progenitor Cell Grafts on Transplantation Outcomes. Biology of Blood and Marrow Transplantation, 2010, 16, 253-262.	2.0	28
50	Killer Cell Immunoglobulin-Like Receptor–Ligand Matching and Outcomes after Unrelated Cord Blood Transplantation in Acute Myeloid Leukemia. Biology of Blood and Marrow Transplantation, 2016, 22, 1284-1289.	2.0	28
51	KIR Donor Selection: Feasibility in Identifying better Donors. Biology of Blood and Marrow Transplantation, 2019, 25, e28-e32.	2.0	28
52	Recovery of Unrelated Donors of Peripheral Blood Stem Cells versus Recovery of Unrelated Donors of Bone Marrow: A Prespecified Analysis from the Phase III Blood and Marrow Transplant Clinical Trials Network Protocol 0201. Biology of Blood and Marrow Transplantation, 2016, 22, 1108-1116.	2.0	26
53	Estimating KIR Haplotype Frequencies on a Cohort of 10,000 Individuals: A Comprehensive Study on Population Variations, Typing Resolutions, and Reference Haplotypes. PLoS ONE, 2016, 11, e0163973.	2.5	26
54	The limitations of qPCR telomere length measurement in diagnosing dyskeratosis congenita. Molecular Genetics & Genomic Medicine, 2016, 4, 475-479.	1.2	20

#	Article	IF	CITATIONS
55	HLA-B Leader and Survivorship after HLA-Mismatched Unrelated Donor Transplantation. Blood, 2020, 136, 362-369.	1.4	20
56	Impact of Previously Unrecognized HLA Mismatches Using Ultrahigh Resolution Typing in Unrelated Donor Hematopoietic Cell Transplantation. Journal of Clinical Oncology, 2021, 39, 2397-2409.	1.6	19
57	Mapping MHC-Resident Transplantation Determinants. Biology of Blood and Marrow Transplantation, 2007, 13, 986-995.	2.0	15
58	Genetic association with B-cell acute lymphoblastic leukemia in allogeneic transplant patients differs by age and sex. Blood Advances, 2017, 1, 1717-1728.	5.2	15
59	Impact of T Cell Dose on Outcome of T Cell-Replete HLA-Matched Allogeneic Peripheral Blood Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2019, 25, 1875-1883.	2.0	14
60	Chain-terminating natural mutations affect the function of activating KIR receptors 3DS1 and 2DS3. Immunogenetics, 2007, 59, 779-792.	2.4	13
61	Recipient HLA-C Haplotypes and microRNA 148a/b Binding Sites Have No Impact on Allogeneic Hematopoietic Cell Transplantation Outcomes. Biology of Blood and Marrow Transplantation, 2017, 23, 153-160.	2.0	12
62	High Resolution HLA Matched Unrelated Donor Versus HLA Identical Sibling Transplantation for Chronic Phase CML Blood, 2007, 110, 171-171.	1.4	12
63	Toll-Like Receptor Polymorphisms in Allogeneic Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation, 2015, 21, 259-265.	2.0	11
64	Chromosome Y–encoded antigens associate with acute graft-versus-host disease in sex-mismatched stem cell transplant. Blood Advances, 2018, 2, 2419-2429.	5.2	11
65	Cytotoxic T-Lymphocyte Antigen-4 Single Nucleotide Polymorphisms Are Not Associated with Outcomes after Unrelated Donor Transplantation: A Center for International Blood and Marrow Transplant Research Analysis. Biology of Blood and Marrow Transplantation, 2014, 20, 900-903.	2.0	10
66	Blueprint for the discovery of biomarkers of toxicity and efficacy for CAR T cells and T-cell engagers. Blood Advances, 2021, 5, 2519-2522.	5.2	10
67	Analysis of a Genetic Polymorphism in the CostimulatoryÂMolecule TNFSF4 with Hematopoietic StemÂCellÂTransplant Outcomes. Biology of Blood and Marrow Transplantation, 2016, 22, 27-36.	2.0	9
68	HLA mismatches and hematopoietic cell transplantation: structural simulations assess the impact of changes in pep-tide binding specificity on transplant outcome. Immunome Research, 2011, 7, 4.	0.1	9
69	Race and Survival in Unrelated Hematopoietic Cell Transplantation. Transplantation and Cellular Therapy, 2022, 28, 357.e1-357.e6.	1.2	9
70	Progress toward curing HIV infection with hematopoietic cell transplantation. Stem Cells and Cloning: Advances and Applications, 2015, 8, 109.	2.3	8
71	Upper gastrointestinal acute graft- <i>versus</i> -host disease adds minimal prognostic value in isolation or with other graft- <i>versus</i> -host disease symptoms as currently diagnosed and treated. Haematologica, 2018, 103, 1708-1719.	3.5	8
72	Genome-Wide Association Analyses Identify Variants in IRF4 Associated With Acute Myeloid Leukemia and Myelodysplastic Syndrome Susceptibility. Frontiers in Genetics, 2021, 12, 554948.	2.3	8

#	Article	IF	CITATIONS
73	Following Transplantation for Acute Myelogenous Leukemia, Donor <i>KIR Cen B02</i> Better Protects against Relapse than <i>KIR Cen B01</i> . Journal of Immunology, 2021, 206, 3064-3072.	0.8	8
74	Classification of HLA-Matching for Retrospective Analysis of Unrelated Donor Transplantation: Revised Definitions To Predict Survival Blood, 2007, 110, 45-45.	1.4	8
75	Regarding "Recipients Receiving Better HLA-Matched Hematopoietic Cell Transplantation Grafts, Uncovered by a Novel HLA Typing Method, Have Superior Survival: A Retrospective Study― Biology of Blood and Marrow Transplantation, 2019, 25, e268-e269.	2.0	7
76	Novel Genetic Variants Associated with Death Due to Acute Lymphoblastic Leukemia Within One Year after HLA-Matched Unrelated Donor Blood and Marrow Transplantation (DISCOVeRY-BMT Study). Biology of Blood and Marrow Transplantation, 2017, 23, S18.	2.0	6
77	HLA mismatches that are identical for the antigen recognition domain are less immunogenic. Bone Marrow Transplantation, 2018, 53, 729-740.	2.4	5
78	A cureâ€rate model for Qâ€learning: Estimating an adaptive immunosuppressant treatment strategy for allogeneic hematopoietic cell transplant patients. Biometrical Journal, 2019, 61, 442-453.	1.0	5
79	Analysis of the Whole CDR3 T Cell Receptor Repertoire after Hematopoietic Stem Cell Transplantation in 2 Clinical Cohorts. Biology of Blood and Marrow Transplantation, 2020, 26, 1050-1070.	2.0	5
80	Current Knowledge and Practice of Pediatric Providers in Umbilical Cord Blood Banking. Clinical Pediatrics, 2018, 57, 161-167.	0.8	4
81	Genetics of HLA Peptide Presentation and Impact on Outcomes in HLA-Matched Allogeneic Hematopoietic Cell Transplantation. Transplantation and Cellular Therapy, 2021, 27, 591-599.	1.2	4
82	Single or Multiple HLA-A, B, C or DRB1 Mismatches Limit Success of Unrelated Donor Bone Marrow Transplantation Blood, 2006, 108, 172-172.	1.4	4
83	Functional Single Nucleotide Polymorphisms (SNPs) in the Major Histocompatibility Complex (MHC) Class II Region Are Associated with Overall Survival (OS) after HLA Matched Unrelated Donor BMT: Results from the Discovery-BMT Study. Biology of Blood and Marrow Transplantation, 2016, 22, S72-S73.	2.0	3
84	The Detection of Donor-Directed, HLA-Specific Alloantibodies in Recipients of Unrelated Hematopoietic Cell Transplantation Is Predictive of Graft Failure Blood, 2007, 110, 475-475.	1.4	3

#	Article	IF	CITATIONS
91	Natural Killer Cell Alloreactivity Predicted By Killer Cell Immunoglobulin-Like Receptor Ligand Mismatch Does Not Impact Engraftment in Umbilical Cord Blood and Haploidentical Stem Cell Transplantation. Transplantation and Cellular Therapy, 2022, 28, 483.e1-483.e7.	1.2	2
92	Trends In Incidence, Presentation, and Outcomes Of Chronic Graft-Versus-Host Disease In Allogeneic Transplantation- Report From The Center For International Blood and Marrow Transplant Research. Blood, 2013, 122, 3309-3309.	1.4	1
93	Selection of Donors with Favorable KIR B Genotypes for Unrelated Hematopoietic Cell Transplantation Results in Superior Relapse Protection and Better Relapse-Free Survival for Patients with AML Blood, 2009, 114, 665-665.	1.4	1
94	Unrelated Donor Registry HLA Match Likelihoods in the Mismatched Setting. Transplantation and Cellular Therapy, 2022, 28, S261-S262.	1.2	1
95	Sensitization to HY-Antigen in Female Donors Was Not Associated with the Post-Transplant HY-IgG Development Nor Clinical Outcomes in Sex-Mismatched Transplantation. Biology of Blood and Marrow Transplantation, 2014, 20, S54-S55.	2.0	Ο
96	MHC Class I Chain-Related Gene a (MICA) Donor-Recipient Mismatches and MICA-129 Polymorphism in Unrelated Donor Hematopoietic Stem Cell Transplants (HSCT) for Hematological Malignancies: A CIBMTR Study. Biology of Blood and Marrow Transplantation, 2015, 21, S156-S157.	2.0	0
97	Genome-Wide Association Study of Cause-Specific Transplant-Related Mortality (TRM) after HLA-Matched Unrelated Donor Allogeneic BMT for Acute Leukemia or Myelodysplastic Syndrome Demonstrates Unique, Non-Overlapping Genetic Associations (Discovery-BMT). Biology of Blood and Marrow Transplantation, 2016, 22, S74-S75	2.0	Ο
98	OR18 Full gene sequencing reveals very limited variation in the regions outside of the antigen recognition domains (ARD) of 360 unrelated hematopoietic stem cell transplant donor-recipient pairs matched for 10/10 at high resolution. Human Immunology, 2016, 77, 15.	2.4	0
99	OR43 Frequency of HLA DPA1 and DPB1 mismatching in a population of 1199 pairs of presumed HLA identical sibling transplant pairs. Human Immunology, 2016, 77, 37.	2.4	Ο
100	Analytical Validation of a Relative Average Telomere Length Assay in a Donor Population for Hematopoietic Stem Cell Transplant (HCT). Biology of Blood and Marrow Transplantation, 2016, 22, S306.	2.0	0
101	Role for Pediatric Providers in Promotion of Umbilical Cord Blood Banking - Potential Untapped Resource?. Biology of Blood and Marrow Transplantation, 2016, 22, S419-S420.	2.0	Ο
102	Functional Genetic Variants on 14Q32 Associate with Death Due to Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) Within One Year after HLA-Matched Unrelated Donor Blood and Marrow Transplantation (DISCOVeRY-BMT Study). Biology of Blood and Marrow Transplantation, 2017, 23, S99-S100.	2.0	0
103	HLA Specificities and Predisposition to the Development of Multiple Myeloma (MM) Blood, 2008, 112, 1688-1688.	1.4	Ο
104	Chronic Graft-Versus-Host Disease Risk Score: A CIBMTR Analysis. Blood, 2010, 116, 898-898.	1.4	0
105	Risk Factors for Major Transplant Related Outcomes In Pediatric Patients with Chronic Graft-Versus-Host Disease. Blood, 2010, 116, 211-211.	1.4	0
106	HLA DR15 Antigen Status Does Not Impact Graft-Versus-Host Disease or Disease-Free Survival in HLA-Matched Sibling Transplantation for Hematologic Malignancies. Blood, 2011, 118, 3094-3094.	1.4	0
107	Amino Acid Substitution At Peptide-Binding Pockets of HLA Class I Molecules Adversely Impacts Hematopoietic Cell Transplantation Outcomes. Blood, 2012, 120, 467-467.	1.4	0
108	Identification of High Risk HLA Class I Amino Acid Substitutions in Hematopoietic Stem Cell Transplantation Blood, 2012, 120, 3050-3050.	1.4	0

#	Article	IF	CITATIONS
109	Recipient HLA-C1 Enhances The Clinical Advantage Of Killer-Cell Immunoglobulin-Like Receptor B haplotype Donors In Myeloablative Unrelated Transplantation For Acute Myelogenous Leukemia. Blood, 2013, 122, 549-549.	1.4	0
110	Cryopreservation of Allogeneic Hematopoietic Cell Grafts Did Not Adversely Impact Early Post-Transplant Survival during the First Six Months of the COVID-19 Pandemic. Transplantation and Cellular Therapy, 2022, 28, S75-S76.	1.2	0